Skip to main content

Table 1 Basic characteristics of the studies enrolled

From: Prognostic impact of platelet-to-lymphocyte ratio on diffuse large B-cell lymphoma: a meta-analysis

Author Year Country Ethnicity Sample size Sex (M/F) Age (year)
Median (range)
Stage Treatment Cut-off Duration NOS score Survival outcome
Melchardt 2015 Austria Caucasian 515 270/245 65 (20–92) I–IV R-CHOP 435 2004–2014 8 OS
Ni 2016 China Asian 59 36/23 54 (14–75) I–IV R-CHOP 270 2009–2015 8 OS, PFS
Perisa 2016 Croatia Caucasian 103 37/66 63 (22–87) I–IV R-CHOP 162 2006–2015 7 OS, PFS
Hao 2017 China Asian 252 165/87 49 (16–82) I–-IV R-CHOP/CHOP 150 2003–2014 8 OS, PFS
Han 2018 China Asian 361 203/158 55 (12–91) III–IV R-CHOP/CHOP 300 2006–2012 6 OS, PFS
Wang 2018 China Asian 182 96/86 59 (18–80) I–IV R-CHOP 150 2005–2016 7 OS, PFS
Zhao 2018 China Asian 309 186/123 58 (16–90) I–IV R-CHOP 170 2009–2015 7 OS, PFS
Lin 2019 China Asian 150 96/54 56 (15–94) I–IV R-CHOP/CHOP 143 2013–2017 6 OS, PFS
  1. R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; OS: overall survival; PFS: progression-free survival